Wave Life Sciences Ltd.
Company Stats
- Market Cap
- $729.1M
- as of Sep 30, 2026
- Shares Outstanding
- 197.0M
- Free Float
- 41.4%
Income Statement
- Revenue
- $42.7M
- Operating Income
- -$215.4M
- Net Income
- -$204.4M
- EBITDA
- -$211.9M
- Revenue Growth, 3Y
- 127.1%
- FCF Margin, 3Y Avg
- -199.6%
- FCF Margin, Worst Year
- -440.5%
Cash Flow
- Free Cash Flow
- -$188.2M
- FCF Yield
- -25.8%
- Owner FCF Yield
- -29.2%
Balance Sheet
- Cash & Equivalents
- $602.1M
Returns & Capital
- SBC, 3Y Avg
- $16.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $42.7M | -$188.2M | -440.5% |
| FY2024 | $108.3M | -$152.0M | -140.3% |
| FY2023 | $113.3M | -$20.5M | -18.1% |
| FY2022 | $3.6M | -$129.1M | -3539.1% |
| FY2021 | $41.0M | -$89.6M | -218.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back